Synthetic Stem Cells Comprehensive Study by Application (Cardiovascular Diseases, Neurological Disorders, Cancer, Diabetes, Musculoskeletal Disorders, Gastrointestinal Disorders, Ocular Disorders), Stem Cell Type (Totipotent, Pluripotent, Multipotent, Oligopotent, Unipotent), Tissue Types (The Brain, Bone Marrow, Blood and Blood Vessels, Skeletal Muscles, Skin, The Liver), End User (Pharmaceutical and Biotechnology Companies, Hospitals and Surgical Centres, Academic Institutes, Research Laboratories, Contract Research Organizations, Others) Players and Region - Global Market Outlook to 2030

Synthetic Stem Cells Market by XX Submarkets | Forecast Years 2024-2030  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Synthetic Stem Cells
Various types of adult stem cells in regenerative medicines have generated considerable attention and interest among clinicians and industries. There has been a groundswell of interest in stem cell-targeted therapies in medicine and neurology among researchers. However, the huge therapeutic edges these have still lack substantial scientific proof and consistent clinical backing. Challenges of careful packaging and process before they're used except vital risks natural stem cells entail are factors that account for their limited therapeutic efficacy. Additionally, they suffer from restricted durability. Hence, there has been a surge in analysis on synthetic stem cells in recent years to urge over a number of these challenges. Synthetic stem cells enable flexibility in producing processes, are less delicate in handling, and might be created to bypass the system. Moreover, they need comparable therapeutic edges offered by natural stem cells in tissue repair. One in every one of the areas wherever synthetic stem cells are witnessing a large potential in cardiovascular diseases.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Synthetic Stem Cells market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Athersys, Inc. (United States), BrainStorm Cell Limited (United States), Caladrius (United States), Cellular Biomedicine Group (United States), Gamida Cell (Israel), Pluristem Therapeutics Inc. (Israel), Sangamo Therapeutics (United States) and ThermoGenesis Corp. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Vericel Corporation (United States), VistaGen Therapeutics, Inc. (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Synthetic Stem Cells market by , Application (Cardiovascular Diseases, Neurological Disorders, Cancer, Diabetes, Musculoskeletal Disorders, Gastrointestinal Disorders and Ocular Disorders) and Region.



On the basis of geography, the market of Synthetic Stem Cells has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Stem Cell Type, the sub-segment i.e. Totipotent will boost the Synthetic Stem Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tissue Types, the sub-segment i.e. The Brain will boost the Synthetic Stem Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Pharmaceutical and Biotechnology Companies will boost the Synthetic Stem Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Awareness About the Synthetic Stem Cells

Market Growth Drivers:
Growing Number of Ethical Concerns Regarding Embryonic Stem Cells

Challenges:
Lack of Awareness

Restraints:
Stringent Rules and Regulations

Opportunities:
Surging Levels of Investment for Research Activities and Growing Number of Applications in Major Indication

Market Leaders and their expansionary development strategies
In October 2023, -QHP Capital, announced its acquisition of Applied StemCell, Inc., a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products.
In April 2023, Regenerative medicine the process of replacing, engineering or regenerating human cells, tissues or organs holds exciting potential for the field of health care. It could someday make it possible to grow a new kidney in a petri dish, repair damaged nerve cells, or reverse memory loss.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Synthetic Stem Cells, Venture Capitalists and Private Equity Firms and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Cardiovascular Diseases
  • Neurological Disorders
  • Cancer
  • Diabetes
  • Musculoskeletal Disorders
  • Gastrointestinal Disorders
  • Ocular Disorders
By Stem Cell Type
  • Totipotent
  • Pluripotent
  • Multipotent
  • Oligopotent
  • Unipotent

By Tissue Types
  • The Brain
  • Bone Marrow
  • Blood and Blood Vessels
  • Skeletal Muscles
  • Skin
  • The Liver

By End User
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Surgical Centres
  • Academic Institutes
  • Research Laboratories
  • Contract Research Organizations
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of Ethical Concerns Regarding Embryonic Stem Cells
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness About the Synthetic Stem Cells
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Synthetic Stem Cells, by Application, Stem Cell Type, Tissue Types, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Synthetic Stem Cells (Value)
      • 5.2.1. Global Synthetic Stem Cells by: Application (Value)
        • 5.2.1.1. Cardiovascular Diseases
        • 5.2.1.2. Neurological Disorders
        • 5.2.1.3. Cancer
        • 5.2.1.4. Diabetes
        • 5.2.1.5. Musculoskeletal Disorders
        • 5.2.1.6. Gastrointestinal Disorders
        • 5.2.1.7. Ocular Disorders
      • 5.2.2. Global Synthetic Stem Cells by: Stem Cell Type (Value)
        • 5.2.2.1. Totipotent
        • 5.2.2.2. Pluripotent
        • 5.2.2.3. Multipotent
        • 5.2.2.4. Oligopotent
        • 5.2.2.5. Unipotent
      • 5.2.3. Global Synthetic Stem Cells by: Tissue Types (Value)
        • 5.2.3.1. The Brain
        • 5.2.3.2. Bone Marrow
        • 5.2.3.3. Blood and Blood Vessels
        • 5.2.3.4. Skeletal Muscles
        • 5.2.3.5. Skin
        • 5.2.3.6. The Liver
      • 5.2.4. Global Synthetic Stem Cells by: End User (Value)
        • 5.2.4.1. Pharmaceutical and Biotechnology Companies
        • 5.2.4.2. Hospitals and Surgical Centres
        • 5.2.4.3. Academic Institutes
        • 5.2.4.4. Research Laboratories
        • 5.2.4.5. Contract Research Organizations
        • 5.2.4.6. Others
      • 5.2.5. Global Synthetic Stem Cells Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Synthetic Stem Cells (Price)
  • 6. Synthetic Stem Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Athersys, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BrainStorm Cell Limited (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Caladrius (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cellular Biomedicine Group (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Gamida Cell (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pluristem Therapeutics Inc. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sangamo Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. ThermoGenesis Corp. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Synthetic Stem Cells Sale, by Application, Stem Cell Type, Tissue Types, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Synthetic Stem Cells (Value)
      • 7.2.1. Global Synthetic Stem Cells by: Application (Value)
        • 7.2.1.1. Cardiovascular Diseases
        • 7.2.1.2. Neurological Disorders
        • 7.2.1.3. Cancer
        • 7.2.1.4. Diabetes
        • 7.2.1.5. Musculoskeletal Disorders
        • 7.2.1.6. Gastrointestinal Disorders
        • 7.2.1.7. Ocular Disorders
      • 7.2.2. Global Synthetic Stem Cells by: Stem Cell Type (Value)
        • 7.2.2.1. Totipotent
        • 7.2.2.2. Pluripotent
        • 7.2.2.3. Multipotent
        • 7.2.2.4. Oligopotent
        • 7.2.2.5. Unipotent
      • 7.2.3. Global Synthetic Stem Cells by: Tissue Types (Value)
        • 7.2.3.1. The Brain
        • 7.2.3.2. Bone Marrow
        • 7.2.3.3. Blood and Blood Vessels
        • 7.2.3.4. Skeletal Muscles
        • 7.2.3.5. Skin
        • 7.2.3.6. The Liver
      • 7.2.4. Global Synthetic Stem Cells by: End User (Value)
        • 7.2.4.1. Pharmaceutical and Biotechnology Companies
        • 7.2.4.2. Hospitals and Surgical Centres
        • 7.2.4.3. Academic Institutes
        • 7.2.4.4. Research Laboratories
        • 7.2.4.5. Contract Research Organizations
        • 7.2.4.6. Others
      • 7.2.5. Global Synthetic Stem Cells Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Synthetic Stem Cells (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Synthetic Stem Cells: by Application(USD Million)
  • Table 2. Synthetic Stem Cells Cardiovascular Diseases , by Region USD Million (2018-2023)
  • Table 3. Synthetic Stem Cells Neurological Disorders , by Region USD Million (2018-2023)
  • Table 4. Synthetic Stem Cells Cancer , by Region USD Million (2018-2023)
  • Table 5. Synthetic Stem Cells Diabetes , by Region USD Million (2018-2023)
  • Table 6. Synthetic Stem Cells Musculoskeletal Disorders , by Region USD Million (2018-2023)
  • Table 7. Synthetic Stem Cells Gastrointestinal Disorders , by Region USD Million (2018-2023)
  • Table 8. Synthetic Stem Cells Ocular Disorders , by Region USD Million (2018-2023)
  • Table 9. Synthetic Stem Cells: by Stem Cell Type(USD Million)
  • Table 10. Synthetic Stem Cells Totipotent , by Region USD Million (2018-2023)
  • Table 11. Synthetic Stem Cells Pluripotent , by Region USD Million (2018-2023)
  • Table 12. Synthetic Stem Cells Multipotent , by Region USD Million (2018-2023)
  • Table 13. Synthetic Stem Cells Oligopotent , by Region USD Million (2018-2023)
  • Table 14. Synthetic Stem Cells Unipotent , by Region USD Million (2018-2023)
  • Table 15. Synthetic Stem Cells: by Tissue Types(USD Million)
  • Table 16. Synthetic Stem Cells The Brain , by Region USD Million (2018-2023)
  • Table 17. Synthetic Stem Cells Bone Marrow , by Region USD Million (2018-2023)
  • Table 18. Synthetic Stem Cells Blood and Blood Vessels , by Region USD Million (2018-2023)
  • Table 19. Synthetic Stem Cells Skeletal Muscles , by Region USD Million (2018-2023)
  • Table 20. Synthetic Stem Cells Skin , by Region USD Million (2018-2023)
  • Table 21. Synthetic Stem Cells The Liver , by Region USD Million (2018-2023)
  • Table 22. Synthetic Stem Cells: by End User(USD Million)
  • Table 23. Synthetic Stem Cells Pharmaceutical and Biotechnology Companies , by Region USD Million (2018-2023)
  • Table 24. Synthetic Stem Cells Hospitals and Surgical Centres , by Region USD Million (2018-2023)
  • Table 25. Synthetic Stem Cells Academic Institutes , by Region USD Million (2018-2023)
  • Table 26. Synthetic Stem Cells Research Laboratories , by Region USD Million (2018-2023)
  • Table 27. Synthetic Stem Cells Contract Research Organizations , by Region USD Million (2018-2023)
  • Table 28. Synthetic Stem Cells Others , by Region USD Million (2018-2023)
  • Table 29. South America Synthetic Stem Cells, by Country USD Million (2018-2023)
  • Table 30. South America Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 31. South America Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 32. South America Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 33. South America Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 34. Brazil Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 35. Brazil Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 36. Brazil Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 37. Brazil Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 38. Argentina Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 39. Argentina Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 40. Argentina Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 41. Argentina Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 42. Rest of South America Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 43. Rest of South America Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 44. Rest of South America Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 45. Rest of South America Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 46. Asia Pacific Synthetic Stem Cells, by Country USD Million (2018-2023)
  • Table 47. Asia Pacific Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 48. Asia Pacific Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 49. Asia Pacific Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 50. Asia Pacific Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 51. China Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 52. China Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 53. China Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 54. China Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 55. Japan Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 56. Japan Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 57. Japan Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 58. Japan Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 59. India Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 60. India Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 61. India Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 62. India Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 63. South Korea Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 64. South Korea Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 65. South Korea Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 66. South Korea Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 67. Taiwan Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 68. Taiwan Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 69. Taiwan Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 70. Taiwan Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 71. Australia Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 72. Australia Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 73. Australia Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 74. Australia Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 79. Europe Synthetic Stem Cells, by Country USD Million (2018-2023)
  • Table 80. Europe Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 81. Europe Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 82. Europe Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 83. Europe Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 84. Germany Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 85. Germany Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 86. Germany Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 87. Germany Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 88. France Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 89. France Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 90. France Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 91. France Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 92. Italy Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 93. Italy Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 94. Italy Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 95. Italy Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 96. United Kingdom Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 97. United Kingdom Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 98. United Kingdom Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 99. United Kingdom Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 100. Netherlands Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 101. Netherlands Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 102. Netherlands Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 103. Netherlands Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 104. Rest of Europe Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 105. Rest of Europe Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 106. Rest of Europe Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 107. Rest of Europe Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 108. MEA Synthetic Stem Cells, by Country USD Million (2018-2023)
  • Table 109. MEA Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 110. MEA Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 111. MEA Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 112. MEA Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 113. Middle East Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 114. Middle East Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 115. Middle East Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 116. Middle East Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 117. Africa Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 118. Africa Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 119. Africa Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 120. Africa Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 121. North America Synthetic Stem Cells, by Country USD Million (2018-2023)
  • Table 122. North America Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 123. North America Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 124. North America Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 125. North America Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 126. United States Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 127. United States Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 128. United States Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 129. United States Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 130. Canada Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 131. Canada Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 132. Canada Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 133. Canada Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 134. Mexico Synthetic Stem Cells, by Application USD Million (2018-2023)
  • Table 135. Mexico Synthetic Stem Cells, by Stem Cell Type USD Million (2018-2023)
  • Table 136. Mexico Synthetic Stem Cells, by Tissue Types USD Million (2018-2023)
  • Table 137. Mexico Synthetic Stem Cells, by End User USD Million (2018-2023)
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Synthetic Stem Cells: by Application(USD Million)
  • Table 147. Synthetic Stem Cells Cardiovascular Diseases , by Region USD Million (2025-2030)
  • Table 148. Synthetic Stem Cells Neurological Disorders , by Region USD Million (2025-2030)
  • Table 149. Synthetic Stem Cells Cancer , by Region USD Million (2025-2030)
  • Table 150. Synthetic Stem Cells Diabetes , by Region USD Million (2025-2030)
  • Table 151. Synthetic Stem Cells Musculoskeletal Disorders , by Region USD Million (2025-2030)
  • Table 152. Synthetic Stem Cells Gastrointestinal Disorders , by Region USD Million (2025-2030)
  • Table 153. Synthetic Stem Cells Ocular Disorders , by Region USD Million (2025-2030)
  • Table 154. Synthetic Stem Cells: by Stem Cell Type(USD Million)
  • Table 155. Synthetic Stem Cells Totipotent , by Region USD Million (2025-2030)
  • Table 156. Synthetic Stem Cells Pluripotent , by Region USD Million (2025-2030)
  • Table 157. Synthetic Stem Cells Multipotent , by Region USD Million (2025-2030)
  • Table 158. Synthetic Stem Cells Oligopotent , by Region USD Million (2025-2030)
  • Table 159. Synthetic Stem Cells Unipotent , by Region USD Million (2025-2030)
  • Table 160. Synthetic Stem Cells: by Tissue Types(USD Million)
  • Table 161. Synthetic Stem Cells The Brain , by Region USD Million (2025-2030)
  • Table 162. Synthetic Stem Cells Bone Marrow , by Region USD Million (2025-2030)
  • Table 163. Synthetic Stem Cells Blood and Blood Vessels , by Region USD Million (2025-2030)
  • Table 164. Synthetic Stem Cells Skeletal Muscles , by Region USD Million (2025-2030)
  • Table 165. Synthetic Stem Cells Skin , by Region USD Million (2025-2030)
  • Table 166. Synthetic Stem Cells The Liver , by Region USD Million (2025-2030)
  • Table 167. Synthetic Stem Cells: by End User(USD Million)
  • Table 168. Synthetic Stem Cells Pharmaceutical and Biotechnology Companies , by Region USD Million (2025-2030)
  • Table 169. Synthetic Stem Cells Hospitals and Surgical Centres , by Region USD Million (2025-2030)
  • Table 170. Synthetic Stem Cells Academic Institutes , by Region USD Million (2025-2030)
  • Table 171. Synthetic Stem Cells Research Laboratories , by Region USD Million (2025-2030)
  • Table 172. Synthetic Stem Cells Contract Research Organizations , by Region USD Million (2025-2030)
  • Table 173. Synthetic Stem Cells Others , by Region USD Million (2025-2030)
  • Table 174. South America Synthetic Stem Cells, by Country USD Million (2025-2030)
  • Table 175. South America Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 176. South America Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 177. South America Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 178. South America Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 179. Brazil Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 180. Brazil Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 181. Brazil Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 182. Brazil Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 183. Argentina Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 184. Argentina Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 185. Argentina Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 186. Argentina Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 187. Rest of South America Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 188. Rest of South America Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 189. Rest of South America Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 190. Rest of South America Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 191. Asia Pacific Synthetic Stem Cells, by Country USD Million (2025-2030)
  • Table 192. Asia Pacific Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 193. Asia Pacific Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 194. Asia Pacific Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 195. Asia Pacific Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 196. China Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 197. China Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 198. China Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 199. China Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 200. Japan Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 201. Japan Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 202. Japan Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 203. Japan Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 204. India Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 205. India Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 206. India Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 207. India Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 208. South Korea Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 209. South Korea Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 210. South Korea Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 211. South Korea Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 212. Taiwan Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 213. Taiwan Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 214. Taiwan Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 215. Taiwan Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 216. Australia Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 217. Australia Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 218. Australia Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 219. Australia Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 220. Rest of Asia-Pacific Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 221. Rest of Asia-Pacific Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 222. Rest of Asia-Pacific Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 223. Rest of Asia-Pacific Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 224. Europe Synthetic Stem Cells, by Country USD Million (2025-2030)
  • Table 225. Europe Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 226. Europe Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 227. Europe Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 228. Europe Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 229. Germany Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 230. Germany Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 231. Germany Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 232. Germany Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 233. France Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 234. France Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 235. France Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 236. France Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 237. Italy Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 238. Italy Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 239. Italy Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 240. Italy Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 241. United Kingdom Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 242. United Kingdom Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 243. United Kingdom Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 244. United Kingdom Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 245. Netherlands Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 246. Netherlands Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 247. Netherlands Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 248. Netherlands Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 249. Rest of Europe Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 250. Rest of Europe Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 251. Rest of Europe Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 252. Rest of Europe Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 253. MEA Synthetic Stem Cells, by Country USD Million (2025-2030)
  • Table 254. MEA Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 255. MEA Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 256. MEA Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 257. MEA Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 258. Middle East Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 259. Middle East Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 260. Middle East Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 261. Middle East Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 262. Africa Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 263. Africa Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 264. Africa Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 265. Africa Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 266. North America Synthetic Stem Cells, by Country USD Million (2025-2030)
  • Table 267. North America Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 268. North America Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 269. North America Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 270. North America Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 271. United States Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 272. United States Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 273. United States Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 274. United States Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 275. Canada Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 276. Canada Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 277. Canada Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 278. Canada Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 279. Mexico Synthetic Stem Cells, by Application USD Million (2025-2030)
  • Table 280. Mexico Synthetic Stem Cells, by Stem Cell Type USD Million (2025-2030)
  • Table 281. Mexico Synthetic Stem Cells, by Tissue Types USD Million (2025-2030)
  • Table 282. Mexico Synthetic Stem Cells, by End User USD Million (2025-2030)
  • Table 283. Research Programs/Design for This Report
  • Table 284. Key Data Information from Secondary Sources
  • Table 285. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Synthetic Stem Cells: by Application USD Million (2018-2023)
  • Figure 5. Global Synthetic Stem Cells: by Stem Cell Type USD Million (2018-2023)
  • Figure 6. Global Synthetic Stem Cells: by Tissue Types USD Million (2018-2023)
  • Figure 7. Global Synthetic Stem Cells: by End User USD Million (2018-2023)
  • Figure 8. South America Synthetic Stem Cells Share (%), by Country
  • Figure 9. Asia Pacific Synthetic Stem Cells Share (%), by Country
  • Figure 10. Europe Synthetic Stem Cells Share (%), by Country
  • Figure 11. MEA Synthetic Stem Cells Share (%), by Country
  • Figure 12. North America Synthetic Stem Cells Share (%), by Country
  • Figure 13. Global Synthetic Stem Cells share by Players 2023 (%)
  • Figure 14. Global Synthetic Stem Cells share by Players (Top 3) 2023(%)
  • Figure 15. Global Synthetic Stem Cells share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Athersys, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Athersys, Inc. (United States) Revenue: by Geography 2023
  • Figure 19. BrainStorm Cell Limited (United States) Revenue, Net Income and Gross profit
  • Figure 20. BrainStorm Cell Limited (United States) Revenue: by Geography 2023
  • Figure 21. Caladrius (United States) Revenue, Net Income and Gross profit
  • Figure 22. Caladrius (United States) Revenue: by Geography 2023
  • Figure 23. Cellular Biomedicine Group (United States) Revenue, Net Income and Gross profit
  • Figure 24. Cellular Biomedicine Group (United States) Revenue: by Geography 2023
  • Figure 25. Gamida Cell (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Gamida Cell (Israel) Revenue: by Geography 2023
  • Figure 27. Pluristem Therapeutics Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Pluristem Therapeutics Inc. (Israel) Revenue: by Geography 2023
  • Figure 29. Sangamo Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 30. Sangamo Therapeutics (United States) Revenue: by Geography 2023
  • Figure 31. ThermoGenesis Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 32. ThermoGenesis Corp. (United States) Revenue: by Geography 2023
  • Figure 33. Global Synthetic Stem Cells: by Application USD Million (2025-2030)
  • Figure 34. Global Synthetic Stem Cells: by Stem Cell Type USD Million (2025-2030)
  • Figure 35. Global Synthetic Stem Cells: by Tissue Types USD Million (2025-2030)
  • Figure 36. Global Synthetic Stem Cells: by End User USD Million (2025-2030)
  • Figure 37. South America Synthetic Stem Cells Share (%), by Country
  • Figure 38. Asia Pacific Synthetic Stem Cells Share (%), by Country
  • Figure 39. Europe Synthetic Stem Cells Share (%), by Country
  • Figure 40. MEA Synthetic Stem Cells Share (%), by Country
  • Figure 41. North America Synthetic Stem Cells Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Athersys, Inc. (United States)
  • BrainStorm Cell Limited (United States)
  • Caladrius (United States)
  • Cellular Biomedicine Group (United States)
  • Gamida Cell (Israel)
  • Pluristem Therapeutics Inc. (Israel)
  • Sangamo Therapeutics (United States)
  • ThermoGenesis Corp. (United States)
Additional players considered in the study are as follows:
Vericel Corporation (United States) , VistaGen Therapeutics, Inc. (United States) , Others
Select User Access Type

Key Highlights of Report


Mar 2024 207 Pages 69 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Athersys, Inc. (United States), BrainStorm Cell Limited (United States), Caladrius (United States), Cellular Biomedicine Group (United States), Gamida Cell (Israel), Pluristem Therapeutics Inc. (Israel), Sangamo Therapeutics (United States) and ThermoGenesis Corp. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Awareness About the Synthetic Stem Cells" is seen as one of major influencing trends for Synthetic Stem Cells Market during projected period 2023-2030.
The Synthetic Stem Cells market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Synthetic Stem Cells Market Report?